Polyrhodanine-based nanomaterials for biomedical applications: A review. 2024

Ibrahim Huzyan Hiba, and Jin Kwei Koh, and Chin Wei Lai, and Seyyed Mojtaba Mousavi, and Irfan Anjum Badruddin, and Mohamed Hussien, and Jest Phia Wong
Nanotechnology and Catalysis Research Centre (NANOCAT), Institute for Advanced Studies (IAS), University of Malaya (UM), 50603, Kuala Lumpur, Malaysia.

Rhodanine is a heterocyclic organic compound that has been investigated for its potential biomedical applications, particularly in drug discovery. Rhodanine derivatives have been examined as the medication options for numerous illnesses, including cancer, inflammation, and infectious diseases. Some rhodanine derivatives have also shown promising activity against drug-resistant strains of bacteria and viruses. One of these derivatives is polyrhodanine (PR), a conducting polymer that has gained attention for its biomedical properties. This review article summarises the latest advancements in creating biomaterials based on PR for biosensing, antimicrobial treatments, and anticancer therapies. The distinctive characteristics of PR, such as biocompatibility, biodegradability, and good conductivity, render it an attractive candidate for these applications. The article also explores obstacles and potential future paths for advancing biomaterials made with PR, including synthesis modifications, characterisation techniques, and in vivo evaluation of biocompatibility and efficacy. Overall, as an emerging research topic, this review emphasises the potential of PR as a promising biomaterial for various biomedical applications and provides insights into the contemporary state of research and prospective directions for investigation.

UI MeSH Term Description Entries

Related Publications

Ibrahim Huzyan Hiba, and Jin Kwei Koh, and Chin Wei Lai, and Seyyed Mojtaba Mousavi, and Irfan Anjum Badruddin, and Mohamed Hussien, and Jest Phia Wong
January 2019, Current pharmaceutical design,
Ibrahim Huzyan Hiba, and Jin Kwei Koh, and Chin Wei Lai, and Seyyed Mojtaba Mousavi, and Irfan Anjum Badruddin, and Mohamed Hussien, and Jest Phia Wong
February 2021, Nanomaterials (Basel, Switzerland),
Ibrahim Huzyan Hiba, and Jin Kwei Koh, and Chin Wei Lai, and Seyyed Mojtaba Mousavi, and Irfan Anjum Badruddin, and Mohamed Hussien, and Jest Phia Wong
September 2019, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology,
Ibrahim Huzyan Hiba, and Jin Kwei Koh, and Chin Wei Lai, and Seyyed Mojtaba Mousavi, and Irfan Anjum Badruddin, and Mohamed Hussien, and Jest Phia Wong
March 2023, Nanomedicine (London, England),
Ibrahim Huzyan Hiba, and Jin Kwei Koh, and Chin Wei Lai, and Seyyed Mojtaba Mousavi, and Irfan Anjum Badruddin, and Mohamed Hussien, and Jest Phia Wong
October 2021, Environmental research,
Ibrahim Huzyan Hiba, and Jin Kwei Koh, and Chin Wei Lai, and Seyyed Mojtaba Mousavi, and Irfan Anjum Badruddin, and Mohamed Hussien, and Jest Phia Wong
June 2013, Chemical Society reviews,
Ibrahim Huzyan Hiba, and Jin Kwei Koh, and Chin Wei Lai, and Seyyed Mojtaba Mousavi, and Irfan Anjum Badruddin, and Mohamed Hussien, and Jest Phia Wong
August 2008, Nanomedicine (London, England),
Ibrahim Huzyan Hiba, and Jin Kwei Koh, and Chin Wei Lai, and Seyyed Mojtaba Mousavi, and Irfan Anjum Badruddin, and Mohamed Hussien, and Jest Phia Wong
December 2020, Biotechnology journal,
Ibrahim Huzyan Hiba, and Jin Kwei Koh, and Chin Wei Lai, and Seyyed Mojtaba Mousavi, and Irfan Anjum Badruddin, and Mohamed Hussien, and Jest Phia Wong
May 2021, Biotechnology journal,
Ibrahim Huzyan Hiba, and Jin Kwei Koh, and Chin Wei Lai, and Seyyed Mojtaba Mousavi, and Irfan Anjum Badruddin, and Mohamed Hussien, and Jest Phia Wong
January 2018, Frontiers in pharmacology,
Copied contents to your clipboard!